Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Imdatifan by NiKang Therapeutics for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Imdatifan is under clinical development by NiKang Therapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...